Small molecule drug companies develop low-molecular-weight medicines designed to interact with specific biological targets. These compounds can often enter cells and may be formulated as oral or other conventional dosage forms across a wide range of therapeutic areas.
This category includes companies working on:
Browse 221 UK small molecule drug companies below.
Mitochondrial sulfide-donor therapeutics for obesity and myopathies
MitoRx Therapeutics is a company developing first-in-class small molecule therapeutics that target mitochondrial sulfide signalling, a mechanism implicated in metabolic dysfunction and muscle disease. Its lead programme is an injectable mitochondria-targeted sulfide donor designed to achieve fat loss without lean mass…
Targeting developmentally-silent oncogenic drivers for cancer therapy
Awen Oncology is a Welsh oncology biotechnology company developing first-in-class therapeutics that target cancer-specific proteins derived from developmental genes that are dormant in healthy adult tissue but aberrantly reactivated in tumour cells. The company's platform integrates high-throughput cell and molecular…
Immunometabolism-targeting small molecules for autoimmune disease
Sitryx Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics that modulate immune cell metabolism to achieve disease remission in autoimmune and inflammatory conditions. The company's approach targets novel metabolic enzymes within immune cells, with lead programmes in…
TYK2/JAK1 inhibitor advancing towards Phase 2 psoriasis trials
Sareum is a clinical-stage biotechnology company developing small-molecule kinase inhibitors for autoimmune diseases and cancer. Its lead oral TYK2/JAK1 inhibitor, SDC-1801, completed Phase 1 testing in healthy volunteers and is being prepared for a Phase 2 study in psoriasis. Dosing in its Phase 2-enabling toxicology…
Preclinical CRO for receptor pharmacology and occupancy studies
Gifford Bioscience is a contract research organisation providing receptor pharmacology and occupancy services for preclinical and discovery stage drug development. The company conducts radioligand binding assays, functional GPCR assays, receptor occupancy studies, autoradiography, and surface plasmon resonance using…
Crystal and particle engineering to improve drug performance
CrystecPharma is a pharmaceutical technology company that uses supercritical fluid processing to engineer drug crystals and particles. Its platform improves the dissolution, stability and delivery of small and large molecule medicines, including inhaled powders. The company provides formulation and process development…
Oral NLRP3 inhibitors for cardiovascular and neurologic inflammation
Rezera, formerly NodThera, is a clinical-stage biotechnology company developing small molecule inhibitors of NLRP3, an inflammasome implicated in chronic inflammatory and neurodegenerative disease. Its lead asset, ruvonoflast, is a brain-penetrant oral inhibitor that has completed Phase II trials and is advancing…
Synthetic psilocybin therapy for treatment-resistant depression and PTSD
Compass Pathways is a clinical-stage biopharmaceutical company developing synthetic psilocybin-based treatments for mental health conditions. Its lead candidate, COMP360, is a proprietary synthesised psilocybin formulation administered alongside structured psychological support. COMP360 holds FDA Breakthrough Therapy…
Automated liquid handling and sample management instruments
SPT Labtech is a designer and manufacturer of laboratory automation instruments and consumables for liquid handling, sample preparation, and sample management. Its product portfolio includes nanolitre liquid handling systems for drug discovery and genomics workflows, cryo-electron microscopy sample preparation…
Novel small-molecule anti-fibrinolytic for acute traumatic and surgical bleeding
ClotProtect Therapeutics is a University of Leeds spin-out developing a first-in-class small molecule anti-fibrinolytic to address acute bleeding following trauma and surgery. The company's approach directly inhibits the enzyme responsible for blood clot breakdown, aiming to offer greater efficacy than current…
Global biopharma with major UK R&D and regulatory operations
Pfizer Limited is the principal UK subsidiary of Pfizer Inc., one of the world's largest biopharmaceutical companies. Its Sandwich, Kent site houses pharmaceutical sciences, global clinical supplies, quality assurance, and worldwide safety and regulatory operations serving over 175 markets. A Devices Centre of…
Automated chiral chemistry platform for small molecule drug discovery
LCC Technologies is a drug discovery company providing biopharma partners with access to its platform, which combines a proprietary billion-scale virtual chiral library with AI-driven design and automated high-throughput synthesis. The platform delivers stereodefined, sp3-rich building blocks and drug-like compounds…
Structural chemistry database and software for drug discovery
The Cambridge Crystallographic Data Centre (CCDC) is a non-profit organisation that curates and distributes the Cambridge Structural Database (CSD), the world's repository of experimentally determined small-molecule organic and metal-organic crystal structures, containing over one million entries. Alongside the…
Small molecule MMR inhibitors to enhance tumour immunogenicity
NeoPhore is a UK immuno-oncology company developing first-in-class small molecule inhibitors of the DNA mismatch repair pathway. By transiently blocking MMR, the company's compounds render tumours MMR-deficient and immunogenic, generating neoantigens that stimulate immune responses against cancer. The approach aims to…
European specialty pharma focused on gastroenterology and hepatology
Norgine is a European specialty pharmaceutical company developing, manufacturing, and commercialising medicines across gastroenterology, hepatology, and cancer supportive care. Founded in 1906 and privately owned, the company markets a portfolio of specialty pharmaceutical products and medical devices across Europe,…
AI-powered bioinformatics platform for precision oncology and drug discovery
Rayca Precision develops AI and bioinformatics platforms for precision oncology and drug discovery, using transcriptomic data and deep learning to predict drug responses and stratify cancer patients. The company also provides automated multi-omics analysis for preclinical and clinical research workflows, and works…
Inhaled therapies for COPD and chronic respiratory diseases
Verona Pharma is a biopharmaceutical company developing and commercialising inhaled therapies for chronic respiratory diseases. Its lead product, ensifentrine, is a first-in-class dual inhibitor of PDE3 and PDE4 that combines bronchodilator and non-steroidal anti-inflammatory activity in a single inhaled compound.…
Immunometabolism drugs for autoimmune and inflammatory diseases
Istesso is a drug discovery and development company working in immunometabolism, developing oral small molecule therapies that reprogram cellular metabolism to treat autoimmune and inflammatory conditions. Its lead candidate is a first-in-class metabolic reprogramming agent for rheumatoid arthritis with a dual…
Clinical-stage biopharma improving nucleoside analogue chemotherapy efficacy
NuCana is a clinical-stage biopharmaceutical company developing a pipeline of cancer medicines using proprietary phosphoramidate prodrug chemistry. Its approach transforms established nucleoside analogue chemotherapy agents into modified forms that bypass key tumour resistance mechanisms, delivering higher…
In vitro pharmacology CRO for preclinical drug discovery
Excellerate Bioscience is a contract research organisation specialising in molecular and cellular pharmacology for preclinical drug discovery. The company provides in vitro assay development, biochemical and cell-based screening, target validation, and compound profiling services to pharmaceutical companies,…